ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
NCT ID: NCT00808015
Last Updated: 2015-05-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1373 participants
OBSERVATIONAL
2009-02-28
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients
NCT00794365
Varenicline Observational Investigation In The Cessation of Smoking
NCT00669240
Varenicline (Champix®) Special Investigation (Regulatory Post Marketing Commitment Plan)
NCT01061710
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
NCT00483002
Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking
NCT00594204
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients in routine practice
Patients prescribed Champix by treating physician and then entered into trial
varenicline
Champix will be prescribed as per usual practice and at the sole discretion of the physician
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
varenicline
Champix will be prescribed as per usual practice and at the sole discretion of the physician
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Beijing, Beijing Municipality, China
Pfizer Investigational Site
Beijing, Beijing Municipality, China
Pfizer Investigational Site
Beijing, Beijing Municipality, China
Pfizer Investigational Site
Guangzhou, Guangdong, China
Pfizer Investigational Site
Guangzhou, Guangdong, China
Pfizer Investigational Site
Guangzhou, Guangdong, China
Pfizer Investigational Site
Shenzhen, Guangdong, China
Pfizer Investigational Site
Wuhan, Hubei, China
Pfizer Investigational Site
Changsha, Hunan, China
Pfizer Investigational Site
Nanjing, Jiangsu, China
Pfizer Investigational Site
Suzhou, Jiangsu, China
Pfizer Investigational Site
Shenyang, Liaoning, China
Pfizer Investigational Site
Shenyang, Liaoning, China
Pfizer Investigational Site
Shenyang, Liaoning, China
Pfizer Investigational Site
Shenyang, Liaoning, China
Pfizer Investigational Site
Xi'an, Shaanxi, China
Pfizer Investigational Site
Xi'an, Shaanxi, China
Pfizer Investigational Site
Xi'an, Shaanxi, China
Pfizer Investigational Site
Xi'an, Shaanxi, China
Pfizer Investigational Site
Taiyuan, Shanxi, China
Pfizer Investigational Site
Chengdu, Sichuan, China
Pfizer Investigational Site
Tianjin, Tianjin Municipality, China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Beijing, , China
Pfizer Investigational Site
Nanning, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shanghai, , China
Pfizer Investigational Site
Shijiazhuang, , China
Pfizer Investigational Site
Tianjin, , China
Pfizer Investigational Site
Tianjin, , China
Pfizer Investigational Site
Tianjin, , China
Pfizer Investigational Site
Wuhan, , China
Pfizer Investigational Site
Hyderabad, Andhra Pradesh, India
Pfizer Investigational Site
Ahmedabad, Gujarat, India
Pfizer Investigational Site
Kochi, Kerala, India
Pfizer Investigational Site
Tthiruvananthapuram, Kerala, India
Pfizer Investigational Site
Mumbai, Maharashtra, India
Pfizer Investigational Site
Mumbai, Maharashtra, India
Pfizer Investigational Site
Mumbai, Maharashtra, India
Pfizer Investigational Site
Mumbai, Maharashtra, India
Pfizer Investigational Site
Delhi, National Capital Territory of Delhi, India
Pfizer Investigational Site
New Delhi, National Capital Territory of Delhi, India
Pfizer Investigational Site
Daryāganj, New Delhi, India
Pfizer Investigational Site
Delhi, New Delhi, India
Pfizer Investigational Site
Delhi, New Delhi, India
Pfizer Investigational Site
Delhi, New Delhi, India
Pfizer Investigational Site
New Delhi, New Delhi, India
Pfizer Investigational Site
Coimbatore, Tamil Nadu, India
Pfizer Investigational Site
Chennai, , India
Pfizer Investigational Site
San Juan City, Batangas, Philippines
Pfizer Investigational Site
Batac, Ilocos Norte, Philippines
Pfizer Investigational Site
San Fernando City, La Union, Philippines
Pfizer Investigational Site
Angeles City, Pampanga, Philippines
Pfizer Investigational Site
Urdaneta, Pangasinan, Philippines
Pfizer Investigational Site
Tarlac City, Tarlac, Philippines
Pfizer Investigational Site
Davao City, , Philippines
Pfizer Investigational Site
Marikina City, , Philippines
Pfizer Investigational Site
Pasay, , Philippines
Pfizer Investigational Site
Quezon City, , Philippines
Pfizer Investigational Site
Quezon City, , Philippines
Pfizer Investigational Site
Quezon City, , Philippines
Pfizer Investigational Site
Cheonan-si, Chungcheongnam-do, South Korea
Pfizer Investigational Site
Goyang-si, Gyeonggi-do, South Korea
Pfizer Investigational Site
Seongnam-si, Gyeonggi-do, South Korea
Pfizer Investigational Site
Suwon, Gyeonggi-do, South Korea
Pfizer Investigational Site
Yangsan, Gyeongsangnam-do, South Korea
Pfizer Investigational Site
Iksan-Si, Jeollabuk-do, South Korea
Pfizer Investigational Site
Daegu, , South Korea
Pfizer Investigational Site
Daegu, , South Korea
Pfizer Investigational Site
Daegu, , South Korea
Pfizer Investigational Site
Daejeon, , South Korea
Pfizer Investigational Site
Daejeon, , South Korea
Pfizer Investigational Site
Incheon, , South Korea
Pfizer Investigational Site
Incheon, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Suwon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3051112
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.